Johnson & Johnson (LIM:JNJ) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LIM:JNJ Johnson & Johnson LIM:JNJ
74 GF Score
Price $265.00
GF Value $202.82
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Johnson & Johnson FFO per Share?

FFO per Share only applies to REITs.

LIM:JNJ
74GF Score
Johnson & Johnson LIM:JNJ
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Johnson & Johnson (LIM:JNJ) Overvalued in 2026?

Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued. The current stock price of $265.00 is trading 30.7% above its estimated GF Value™ of $202.82. GuruFocus considers Johnson & Johnson to be Significantly Overvalued.

Key valuation signals for LIM:JNJ:

  • FFO per Share:
  • GF Value™: $202.82 vs. price of $265.00 (30.7% above fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the LIM:JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Johnson & Johnson Business Description

Address One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
74GF Score

Get the complete analysis for LIM:JNJ

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$265.00
Price
$202.82
GF Value